BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Recipharm AB Enters Into a New Development and Manufacturing Collaboration With Vetcare


11/19/2012 6:46:38 AM

19th November 2012: Recipharm and Vetcare have today announced the signing of an agreement for the development and manufacture of a parenteral veterinary product. Specifically, the product concerned will be developed by Recipharm’s development site in Solna, Sweden and the commercial manufacturing is intended to take place at the company’s site in Monts, France.

Maria Lundberg, General Manager, Recipharm Pharmaceutical Development, commented: “We are pleased to have entered into this collaboration with Vetcare. This project is perfectly suited to Recipharm as it allows us to demonstrate our expertise in formulation and analytical method development with a challenging formulation before performing technology transfer to commercial manufacturing”.

“Michel Saudemon, General Manager of Recipharm in Monts added “this project is excellent news and is a perfect fit for our new smaller scale flexible manufacturing facility which will come on line next year”.

Kalevi Heinonen, Managing Director of Vetcare Oy, commented: “We view this as a highly important industry collaboration that will allow us to launch a novel product with the potential for significant improvement in animal health in the most efficient way. It was vital to us that we partnered with a company that could offer us both development and commercial manufacturing. Also the geographical locations, Sweden and France, are very suitable for us.

About Recipharm

Recipharm AB is a leading contract development and manufacturing organisation

(CDMO) based in Sweden employing some 1,700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.

Recipharm’s Pharmaceutical Development Services group offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities.

For more information visit; www.recipharm.com

About Vetcare Oy

Vetcare is a privately owned Finnish company specialised for veterinary products (both pharmaceuticals and non-pharmaceuticals). It is the third largest veterinary pharma company in Finland. Vetcare is also nowadays one of the leading companies developing veterinary pharmaceuticals in Finland.

For more information visit; www.vetcare.fi

Contact information

Recipharm – Maria Lundberg, General Manager, +46 8 602 52 73

Vetcare – Kalevi Heinonen, Managing Director, +35 8 400 777 212

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail:

t.jervis@defacto.com or a.heeley@defacto.com

Tel: +44 (0) 207 861 3019/3043


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->